Search results
Newron's schizophrenia add-on improves symptoms, charging up case for phase 3 test
FierceBiotech· 2 days agoNewron Pharmaceuticals’ add-on schizophrenia treatment improved both positive and negative symptoms...
Newron’s add-on schizophrenia therapy finds success in Phase II/III trial
Clinical Trials Arena via Yahoo Finance· 24 hours agoThe therapy met endpoints in the Phase II/III trial, with Newron considering a pivotal Phase III...
Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
Investor's Business Daily· 14 hours agoThey're testing drugs for schizophrenia and cognitive impairment tied to the same disease. "Looking...
College student explores rare mental health condition in award-winning podcast
NPR· 1 hour ago"I was one of those people that had this perspective of, 'these people are crazy, these people are...
Spring Has Sprung Obviousness Trends from the Federal Circuit
The National Law Review· 16 hours agoAt the beginning of the month, in Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc....
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 3 hours agoBMS strengthened its neuroscience portfolio with the acquisition of Karuna Therapeutics, and its lead asset, KarXT (trospium chloride + xanomeline), a...
Hainault sword attack: police hunt for motive
The Week via Yahoo News· 23 hours agoThe murder rate has fallen in recent years, but "there has been a rise in the proportion" of perpetrators diagnosed with serious mental illnesses such as...
Scientists restore brain cells impaired by a rare genetic disorder
NPR· 2 days agoThe approach may help researchers develop treatments for other genetic conditions, including some...
My patient thinks he’s a werewolf: 10 years as an NHS psychiatrist
The Telegraph via Yahoo News· 5 hours agoI was once on an aeroplane when the call went out about a medical emergency. It being the only time...
Earnings call: Alkermes reports solid Q1 2024 results, optimistic about pipeline By Investing.com
Investing.com· 10 hours agoThe neuroscience company reported net sales for VIVITROL at $97.7 million, ARISTADA at $78.9...
